The genomic and biological complexity of mixed phenotype acute leukemia
Claire Andrews1, Anne Tierens2, Mark Minden1
1Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Canada.
Abstract:
Mixed phenotype acute leukemia (MPAL) is a heterogeneous group of leukemias that are defined immunophenotypically by antigen expression on blasts of both myeloid and lymphoid lineage. With the exception of BCR-ABL positive and KMT2A rearranged MPAL, the biology of the majority of MPAL remains uncertain. Several recent studies have explored the genomic and epigenetic landscape of MPAL and have suggested a further refinement of the WHO classification to emphasize the genomic heterogeneity of MPAL. Further studies including single cell analysis, whole exome sequencing and time of flight cytometry will provide for further biological characterization. Treatment decisions are complicated due to this lack of classification and the dearth of prospective randomized studies. Acute lymphoblastic leukemia-type therapy appears to achieve higher remission rates, and allogenic stem cell transplantation may be beneficial in a select group of patients in first complete remission. Multi-center collaborations may answer these questions more conclusively. Our review aims to discuss the diagnostic challenges, recent genomic studies and therapeutic strategies in this poorly understood disease.
Insights
Mixed phenotype acute leukemia (MPAL) is complex. Recent genomic studies reveal heterogeneity, impacting diagnosis and treatment strategies for this rare leukemia.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Mixed phenotype acute leukemia (MPAL) is defined by myeloid and lymphoid lineage antigens on blast cells.
- The underlying biology of most MPAL subtypes remains poorly understood, complicating classification and treatment.
- Existing WHO classification may require refinement based on emerging genomic data.
Purpose of the Study:
- To review diagnostic challenges in MPAL.
- To discuss recent genomic and epigenetic studies in MPAL.
- To outline current and potential therapeutic strategies for MPAL.
Main Methods:
- Literature review of diagnostic criteria and immunophenotyping.
- Analysis of recent genomic and epigenetic studies in MPAL.
- Evaluation of treatment outcomes and recommendations for MPAL.
Main Results:
- MPAL is genomically heterogeneous, necessitating refined classification.
- Acute lymphoblastic leukemia-type therapy shows higher remission rates.
- Allogeneic stem cell transplantation may benefit select MPAL patients.
Conclusions:
- Further research, including single-cell analysis and whole exome sequencing, is crucial for biological characterization.
- Multi-center collaborations are needed to conduct prospective randomized studies.
- Refined classification and targeted therapies are essential for improving MPAL patient outcomes.
More Related Videos
10:18From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia
Published on: October 19, 2014
09:34A Combinatorial Single-cell Approach to Characterize the Molecular and Immunophenotypic Heterogeneity of Human Stem and Progenitor Populations
Published on: October 25, 2018
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Disorders of Leukocytes
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
01:15Differentiation of Common Myeloid Progenitor Cells
01:49Multiple Allele Traits